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Introduction {#sec1}
============

Alpha-synuclein (α-Syn) is an aggregation-prone protein implicated in Parkinson's disease (PD). Insoluble α-Syn species are a major component of Lewy bodies, which are proteinaceous inclusions found in post-mortem analyses of PD patient brains ([@bib71]). Amplification and mutations in the gene encoding α-Syn result in dominant familial parkinsonism ([@bib55], [@bib65]). α-Syn is a soluble, cytoplasmic protein that can bind to certain lipids and cellular membranes ([@bib68]). These interactions appear to be important for the normal function of α-Syn and may also play roles in the aggregation of the protein into cytoplasmic inclusions, but the precise molecular events underlying α-Syn neuronal toxicity remain elusive.

The proteotoxicity of α-Syn has been modeled in a variety of systems ([@bib18], [@bib32], [@bib38]), including *Saccharomyces cerevisiae* ([@bib51]), resulting in translatable findings ([@bib12], [@bib77]). In yeast, ectopically expressed α-Syn forms intracellular inclusions and causes dose- and time-dependent cytotoxicity ([@bib51]). Genome-wide screens performed in yeast have identified dozens of genes that upon overexpression or silencing modulate toxicity ([@bib14], [@bib22], [@bib33], [@bib83], [@bib84]). The human homologues of several conserved yeast genes from this set, such as *RAB1* and *NEDD4* ([@bib12], [@bib14]), modulate α-Syn toxicity in neuronal cells, and mutations in another identified gene *ATP13A2* (also known as *PARK9*) cause an autosomal recessive form of PD ([@bib22], [@bib56]). Despite these promising findings and the agreement across species, the molecular mechanisms of genetic modifiers of α-Syn toxicity are largely unknown.

In this study, we sought to systematically identify pathways and biological processes that act downstream of genetic modifiers of α-Syn toxicity. We used a recently developed proteomics approach that enables simultaneous monitoring of activation states of a variety of biological processes ([@bib70]). This approach is based on quantitative detection of sentinel proteins, which are biological markers that change in abundance or phosphorylation state or are cleaved at specific sites in response to changes in activity of the associated pathway. Examples of sentinels are levels of Atg8 or cleavage of Ape1, which are indicators of activation of autophagy ([@bib34], [@bib74]), and phosphorylation of MAP kinases that mark activation of this pathway ([@bib8]).

As sentinels of α-Syn-mediated toxicity, we monitored 269 total markers: 178 sentinels report the activation states of 140 biological processes and 91 sentinels that were selected from shotgun proteomic analyses of α-Syn-perturbed yeast or prior knowledge about α-Syn biology. We analyzed genetically engineered strains that simultaneously express α-Syn and one of 33 different α-Syn genetic modulators. In order to identify pathways that rescue cells from α-Syn-mediated toxicity, we employed a multiple linear regression approach, which implicated Pah1, a phosphatase that catalyzes conversion of phosphatidic acid to diacylglycerol at the endoplasmic reticulum (ER), as an effector of rescue. Thus, a lipid biosynthetic pathway is a potential instrument for amelioration of α-Syn-induced pathology.

Results {#sec2}
=======

Proteome Responses to α-Syn Toxicity in Yeast {#sec2.1}
---------------------------------------------

α-Syn pathobiology can be modeled in yeast by inducible expression of human α-Syn ([@bib51]). Expression of a single α-Syn copy results in its localization to the plasma membrane with no appreciable toxicity, whereas expression of two copies leads to the formation of large cytoplasmic inclusions and inhibition of yeast growth. We performed shotgun proteomics and phosphoproteomics analyses at 6 h post-induction of expression of two copies of α-Syn and of vector control. α-Syn intracellular inclusions were detected in the α-Syn-expressing cells and while growth rate was reduced compared to control cells, α-Syn-expressing cells remained viable ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C). In total, 3,679 proteins and 5,464 phosphopeptides were quantified using a label-free proteomics approach. Levels of 160 proteins and 228 phosphopeptides were significantly different in α-Syn-expressing cells compared to control (fold change ≥ 2, q ≤ 0.01, [Figures S1](#mmc1){ref-type="supplementary-material"}D--S1G; [Table S1](#mmc2){ref-type="supplementary-material"}).

Functional enrichment analyses of regulated proteins and phosphoproteins based on gene ontology (GO) terms and Munich Information Center For Protein Sequences (MIPS) categories revealed differential expression of AGC protein kinase-encoding genes and genes involved in the vacuole, the ER, and the plasma membrane ([Table S2](#mmc3){ref-type="supplementary-material"}), three subcellular locations known to be affected by α-Syn ([@bib22], [@bib54]). Next, we asked whether proteins upregulated in α-Syn-expressing cells were toxic when expressed beyond a certain level by cross-referencing a previously reported dataset ([@bib40]). Four significantly upregulated proteins (Erg2, Erg25, Nce102, and Vma3) are encoded by dosage-sensitive genes, suggesting that α-Syn toxicity could be linked to increased expression of these genes. Of 102 proteins previously shown to be associated with rescue from α-Syn toxicity ([@bib33], [@bib84]), 62 were identified in our screen, and three of these (Cmc2, Pan2, and Osh2) were significantly upregulated ([Table S1](#mmc2){ref-type="supplementary-material"}, red). Upregulation of these genes could counteract toxicity of α-Syn ([@bib14], [@bib22]).

Identification of Pathways that Rescue from α-Syn Toxicity Using an Expanded Sentinel Assay {#sec2.2}
-------------------------------------------------------------------------------------------

The sentinel assay previously developed by our group quantified 202 (phospho)proteins that report known pathway activation events in response to well-characterized perturbations ([@bib70]). We reasoned that monitoring the extent of activation of these pathways in response to expression of genetic modulators of α-Syn toxicity would provide a comprehensive view of their cellular effects. As α-Syn may trigger molecular events not captured by our original assay, we expanded it to include 33 proteins and 66 phosphopeptides that either reacted to the overexpression of α-Syn and were prioritized based on amplitude of response, known functions, and conservation in humans or were previously linked to α-Syn. In the latter set, we included sentinels for a phosphorylation site and three ubiquitination sites on α-Syn since these modifications were implicated in toxicity ([@bib49], [@bib50]) and a marker for the degradation of Cpy1, which has been used as a reporter for an α-Syn-induced vesicle trafficking defect ([@bib14]). We developed targeted quantitative proteomics assays based on parallel reaction monitoring (PRM) mass spectrometry for these proteins ([Tables S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"}).

The expanded sentinel assay was used to analyze effects of 33 genetic modulators of α-Syn identified through previous screens and hypothesis-driven studies ([@bib14], [@bib22], [@bib33], [@bib77], [@bib84]) ([Figure 1](#fig1){ref-type="fig"}A; [Table S5](#mmc6){ref-type="supplementary-material"}). We expressed each genetic modulator together with α-Syn, both under control of a galactose-inducible promoter. After 6 h, we monitored pathway activation. We also quantified the extent of rescue or toxicity enhancement achieved by expression of each genetic modulator compared to cells that did not express the modulator by quantitative analyses of growth curves.Figure 1Relating Growth and Pathway Activation Data through Regression Analysis to Identify Effectors of Rescue from α-Syn-Induced Toxicity(A) Workflow to predict cellular pathways that rescue yeast from α-Syn-induced toxicity. Mod, α-Syn genetic modulator.(B) Sentinel quantification for each α-Syn genetic modulator. Genetic modulators are ordered in columns according to their genetic modulation effect from enhancement of toxicity (blue) to suppression of toxicity (red). aSyn, α-Syn expression without genetic modulation. Phosphopeptide (dark purple) and protein (light purple) pathway sentinels are hierarchically clustered in rows. Log~2~ fold-change (FC) in sentinel abundance relative to vector strain is shown on a color scale of green (decreased) to red (increased). Gray bar denotes cluster of oppositely regulated sentinels. See also [Tables S6](#mmc7){ref-type="supplementary-material"}, [S7](#mmc8){ref-type="supplementary-material"}, and [S8](#mmc9){ref-type="supplementary-material"}.(C) Regression analysis of pathway sentinels and genetic rescue using stability selection in order to identify strongest predictors of rescue. Selection probability ($\widehat{\text{Π}}$) plotted as a function of the regularization parameter (λ) displays stability paths of phosphopeptides (left) and proteins (right). Sentinels that passed the cutoff of selection probability (horizontal red line, 0.6) after fitting a multiple linear regression model are colored: red paths indicate a positive association with rescue, and blue paths indicate a negative association. Corresponding selected pathway sentinels are shown in [Table S12](#mmc13){ref-type="supplementary-material"}.(D) Correlation plots for two sentinel proteins, Adi1 and Pah1. Plots show the extent of rescue relative to the unmodulated α-Syn strain and report on the respective cellular process, heat-shock response and lipid metabolism, as monitored by FC of an Adi1 peptide and the Pah1 peptide containing phosphorylation sites S744 and S748 relative to the vector strain. r, Pearson correlation coefficient. p, p-value from application of the correlation test (n = 37).(E) Schematic of the role of Pah1 in lipid metabolism. Pah1 is dephosphorylated by the Nem1-Spo7 complex to catalyze conversion of PA into DAG. P, Phosphorylation.

We quantified a total of 269 sentinels per genetic modulator ([Figure 1](#fig1){ref-type="fig"}B; [Table S6](#mmc7){ref-type="supplementary-material"}). This consisted of 178 generic pathway markers (140 biological processes) and 91 α-Syn-specific markers, made up of 103 phosphopeptides and 166 proteins. In 88% of cases, expression of genes expected to ameliorate α-Syn-mediated toxicity or to increase toxicity matched findings from previous genetic screens ([Figure S1](#mmc1){ref-type="supplementary-material"}H; [Table S7](#mmc8){ref-type="supplementary-material"}). Clustering based on the similarities of sentinel profiles, revealed that modulators involved in the same cellular process generally grouped together ([Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}I) and that modulators from related processes (e.g., endocytosis and vesicle transport) clustered in proximity. Thus, closely related modulators induce similar downstream effects. The mean Pearson correlation coefficient (r) and the coefficient of determination (R^2^) for sentinel abundances from replicated analysis of unmodulated α-Syn strains were 0.92 and 0.85 for proteins and 0.78 and 0.61 for phosphopeptides, respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}J). We also identified 100 proteins that were oppositely regulated upon expression of genetic enhancers versus genetic suppressors of toxicity ([Figure 1](#fig1){ref-type="fig"}B, gray bar, [Table S8](#mmc9){ref-type="supplementary-material"}) that were enriched for processes previously attributed to α-Syn toxicity such as oxidative stress and protein folding ([Table S9](#mmc10){ref-type="supplementary-material"}).

Next, we identified pathways that best correlated with the extent of rescue based on the abundances of the respective sentinels. Rather than individually correlating the state of each sentinel with rescue of the yeast strain, we used a regularized multiple regression approach that accounted for the fact that multiple pathways together might best explain the phenotypic rescue. We applied sparse linear regression analyses based on lasso with stability selection ([@bib42]) (see [STAR Methods](#sec4){ref-type="sec"}, [Figure 1](#fig1){ref-type="fig"}C; [Tables S10](#mmc11){ref-type="supplementary-material"} and [S11](#mmc12){ref-type="supplementary-material"}). For the majority of proteins and pathways we found no correlation between the extent of rescue and abundance of the associated sentinel ([Figure 1](#fig1){ref-type="fig"}D; left, [Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Correlations were observed for some sentinels ([Figure S2](#mmc1){ref-type="supplementary-material"}C); however, only four phosphoprotein sentinels (Pah1, Num1, She3, and Osh1) and seven protein sentinels (Met10, Ncp1, Car1, Dot5, Gpp1, Ero1, and Cwp1) were predictive of rescue with a selection probability greater than or equal to 60% ([Figure 1](#fig1){ref-type="fig"}C, red and blue, [Figure S2](#mmc1){ref-type="supplementary-material"}D; [Table S12](#mmc13){ref-type="supplementary-material"}). These markers are involved in lipid, sterol, and amino acid metabolism, mitochondria-ER-cortex-anchoring, cell-wall biosynthesis, mRNA transport, cortical ER inheritance, oxidative stress, and protein folding. Biological processes associated with sentinels that correlated with rescue included vesicle-trafficking defects, which were previously shown to be involved in α-Syn toxicity ([@bib14]). Vesicle trafficking was monitored in our assay by the ER-to-Golgi trafficking of the protein Cpy1, which had a selection frequency below 60% but ranked 12th of 166 protein sentinels ([Table S11](#mmc12){ref-type="supplementary-material"}). This indicates that our method captured meaningful biological events associated with α-Syn toxicity.

The top ranked pathway sentinel was phosphorylation of the protein Pah1, a marker for the biosynthesis of diacylglycerol (DAG) ([Figure 1](#fig1){ref-type="fig"}D, right, [Figure S2](#mmc1){ref-type="supplementary-material"}D; [Table S12](#mmc13){ref-type="supplementary-material"}). Dephosphorylation of Pah1 by the Nem1-Spo7 complex is known to activate the enzyme ([@bib48], [@bib72]). Activated Pah1 catalyzes the conversion of phosphatidic acid (PA) to DAG at the ER membrane; inactive Pah1 is localized to the cytosol ([@bib30]) ([Figure 1](#fig1){ref-type="fig"}E). Our data indicate that phosphorylation, and therefore inactivation, of Pah1 positively correlates with rescue from α-Syn toxicity and suggests that Pah1 may act downstream of a broad range of α-Syn genetic modulators.

Network Paths Linking Genetic Modulators to Pah1 {#sec2.3}
------------------------------------------------

Overexpression of several genetic modulators of α-Syn toxicity resulted in the regulation of Pah1 phosphorylation. To assess how diverse genetic modulators are linked to Pah1 phosphorylation, we performed network analyses using the tool, STRING ([@bib75]). We searched in the high-confidence STRING yeast protein association network for the shortest paths between each genetic modulator and six known upstream regulators of Pah1 (Nem1-Spo7, Cdc28, PKA complex, CK2 complex, Pho80-Pho85, and Pkc1) ([Figure 2](#fig2){ref-type="fig"}A). In the resulting subnetwork, 25 genetic modulators were linked to Pah1 regulators whereas eight were not. Shortest path analysis revealed common and disparate downstream paths connecting modulators and Pah1. Modulators known to be involved in the same biological process grouped together in the Pah1 network. Modulators that induced the largest fold changes in Pah1 phosphorylation were direct neighbors or within two edges of a known Pah1 regulator ([Figure S2](#mmc1){ref-type="supplementary-material"}E). For example, the modulators *TIF4631*, *TIF4632*, and *YKT6* are within two edges of the known regulator Pkc1, which phosphorylates Pah1 to stimulate its proteasomal degradation ([@bib29]). Modulators *PDE2* and *HRD1* are within two edges of the PKA complex, which has the opposite effect on Pah1 proteasomal degradation and attenuates its catalytic activity ([@bib73]). *YPT1* and *CDC5* are within two edges of Cdc28, which has not been found to affect Pah1 catalytic activity but does phosphorylate Pah1 and potentially influences its localization ([@bib30]). For some modulators, more than one Pah1 phosphorylation regulator was equally close (i.e., there were multiple paths of the same length) ([Figure 2](#fig2){ref-type="fig"}B; [Table S13](#mmc14){ref-type="supplementary-material"}). 40% of modulators were closest to a single Pah1 regulator, 36% were equidistant to two regulators, and 24% were equidistant to three or four. The most central nodes in the network were Cdc28, Ubi4, Ura2, Tpk1, and Pkc1 ([Table S13](#mmc14){ref-type="supplementary-material"}).Figure 2Network Paths Connecting α-Syn Genetic Modulators to Known Regulators of Pah1(A) A subgraph of nodes included in the shortest paths between α-Syn genetic modulators and their closest target among known Pah1 regulators (Nem1-Spo7, Cdc28, PKA complex, casein kinase II complex, Pho80-85, Pkc1) was obtained using the STRING *Saccharomyces cerevisiae* network. Genetic modulators are colored by a blue to red gradient according to their rescue effect; known Pah1 regulators are colored rings and discovered intermediate nodes are shown in gray. The known Pah1 regulators are 14 proteins involved in six complexes; complex members have matched colors.(B) The closest Pah1 regulator of each modulator is shown (black cell). If more than one Pah1 regulator had the same shortest distance from a genetic modulator, then multiple Pah1 regulators were designated as closest. See also [Table S13](#mmc14){ref-type="supplementary-material"}.

Deletion of *NEM1* Increases Levels of Phosphorylated Pah1 and Suppresses α-Syn Toxicity {#sec2.4}
----------------------------------------------------------------------------------------

We next assessed whether Pah1 phosphorylation is sufficient to ameliorate α-Syn-mediated toxicity. First, we deleted the gene encoding the phosphatase Nem1, which is responsible for dephosphorylation of Pah1 at the two residues identified in our screen and five other residues ([@bib60]). The α-Syn-expressing Δ*nem1* strain grew better than the α-Syn-expressing strain without the deletion, suggesting that phosphorylation of Pah1 promotes cellular fitness in the presence of high levels of α-Syn ([Figure 3](#fig3){ref-type="fig"}A). To confirm that phosphorylation of Pah1 was indeed increased in the α-Syn-expressing Δ*nem1* strain, we measured phosphorylation of Pah1 by targeted mass spectrometry. As expected, Pah1 phosphorylation at known Nem1 target sites, and not at other residues, was significantly increased in the absence of the Nem1 phosphatase ([Figure 3](#fig3){ref-type="fig"}B). Of note, no Δ*nem1*-induced suppression of toxicity was observed in cells expressing aggregation-prone proteins TDP-43 and FUS, indicating that the effect is specific to α-Syn ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Western blot analyses showed that mutants that resulted in Pah1-related rescue or enhanced toxicity did not affect α-Syn expression ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Collectively, these data confirm the prediction resulting from our sentinel analysis that Pah1 phosphorylation specifically counteracts the toxic effects of α-Syn.Figure 3Deletion of *NEM1* Suppresses Toxicity Caused by α-Syn Expression and Alters Inclusion Phenotype(A) Cultures of indicated yeast strains spotted by serial dilution onto glucose and galactose-containing medium. α-Syn expression is under the control of a galactose-inducible promoter.(B) Pah1 phosphorylation levels assessed by targeted proteomic measurement of two phosphopeptides containing three known Nem1-target sites and two phosphopeptides with two residues not targeted by Nem1. See also [Table S14](#mmc15){ref-type="supplementary-material"}. Mean ± standard deviation abundances for two peptides in each group (Nem1 target residues and other residues) in biological triplicates were compared (two-way ANOVA adjusted for multiple comparisons, n = 6, alpha = 0.05).(C) Representative images of cells that express α-Syn-YFP and mutants with opposite effects on Pah1 phosphorylation status. Scale bars represent 10 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}E.(D) Cells with and without α-Syn-YFP inclusions were counted in three fields of view. The mean counts expressed as percentages ± standard deviation of biological replicates were compared (one-way ANOVA adjusted for multiple comparisons, n \> 3, alpha = 0.05). ^∗∗∗∗^, p \< 0.0001.

The Diacylglycerol Branch of Lipid Metabolism Enhances α-Syn Toxicity {#sec2.5}
---------------------------------------------------------------------

α-Syn inclusions are a hallmark of toxicity in the yeast model and are associated with lipids and neutral lipid droplets in yeast and mammalian cells ([@bib13], [@bib51]). Pah1 controls the formation of cytosolic lipid droplets by catalyzing the biosynthesis of DAG, and cells with abrogated Pah1 activity have fewer droplets than control cells ([@bib1]). To determine whether modulation of Pah1 affects α-Syn inclusions, we first established that α-Syn binds lipids in our model by demonstrating co-localization of YFP-tagged α-Syn with Nile red-positive lipids ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Next, we imaged YFP-tagged α-Syn in the Δ*nem1* strain and in the strain expressing *pah1--*7A, a mutant with higher than wild-type activity ([@bib10], [@bib48]). We found that there were significantly fewer cells with large α-Syn inclusions in the Δ*nem1* strain and significantly more in the *pah1--*7A strain relative to the control strain ([Figures 3](#fig3){ref-type="fig"}C, 3D, and [S3](#mmc1){ref-type="supplementary-material"}E). There were fewer inclusions in the Δ*pah1* strain and in the strain in which *PAH1* was replaced with the catalytically inactive mutant *pah1*-D398E than in the control strain ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G) ([@bib26]). Despite modulation of toxicity by deletion of *NEM1* or expression of *pah1--*7A, we observed co-localization of α-Syn with Nile red-positive lipids ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D), and there were fewer lipids in Δ*nem1* cells and more lipids in *pah1--*7A α-Syn-expressing cells than in wild-type cells that expressed α-Syn ([Figure S3](#mmc1){ref-type="supplementary-material"}H). In summary, these data show that α-Syn inclusion formation depends on activation of Pah1.

To confirm that the phosphorylation status of Pah1 has an effect on toxicity, we assayed growth of the *pah1--*7A strain. The growth of yeast perturbed by both α-Syn and *pah1--*7A expression was significantly lower than expected based on each perturbation alone ([Figure 4](#fig4){ref-type="fig"}A), indicating a synergistic interaction between the 7A mutant of Pah1 and α-Syn expression ([Figure 4](#fig4){ref-type="fig"}B). The 7D/E phospho-mimic of Pah1 did not decrease the number of cells with inclusions or rescue growth relative to cells that expressed wild-type Pah1 ([Figures S3](#mmc1){ref-type="supplementary-material"}G, S3I, and S3J). A possible explanation is that this phospho-mimic does not have the same effect as endogenous phosphorylation, a phenomenon known to occur ([@bib52]). Since Δ*pah1* and *pah1*-D398E strains were more resilient than expected to the toxic effects of α-Syn there appears to be an alleviating interaction between these mutations and α-Syn ([Figure 4](#fig4){ref-type="fig"}B). This analysis of *PAH1* mutants further supported our hypothesis that Pah1 deactivation promotes rescue.Figure 4Pah1 Activity in the DAG Branch of Lipid Metabolism Regulates α-Syn Toxicity in Yeast and Mammalian Cells(A) Biomass of *PAH1* mutant-expressing yeast strains grown with or without 1 nM estradiol to induce α-Syn expression were monitored over 24 h. Light scattering (620 nm) measurements were baselined on a well-by-well basis, summed, and divided by mean replicate intensity to obtain normalized biomass values (one-way ANOVA adjusted for multiple comparisons, n = 4, alpha = 0.05).(B) Observed biomass of strains expressing α-Syn and a Pah1 mutant (biomass\[α-Syn + *pah1* mutant\]) was compared to expected biomass based on each perturbation alone (biomass\[α-Syn\]^∗^biomass\[*pah1* mutant\]). Biomass data from (A) were used (two-way ANOVA adjusted for multiple comparisons, alpha = 0.05).(C) Schematic depicting possible downstream effects of phosphorylated Pah1 with inhibitors highlighted in red.(D and E) Normalized biomass of indicated yeast strains measured in the presence or absence of (D) 75 μM inositol (n = 3) or (E) 2 mM propranolol (n ≥ 3; one-way ANOVA adjusted for multiple comparisons, alpha = 0.05).(F) Viability of mouse N2A cells treated with α-Syn fibrils preformed from recombinant protein and then treated for 36 h with vehicle or 10 μM propranolol (two-way ANOVA adjusted for multiple comparisons, n = 4, alpha = 0.05).(G) Viability of HEK293 cells transfected with a pool of siRNAs designed to inhibit expression of *LPIN1-3* and treated with α-Syn fibrils (unpaired t test, n = 6, alpha = 0.05).Normalized biomass and cell viability values are displayed as mean ± standard deviation. ^∗∗∗∗^, p \< 0.0001; ^∗∗∗^, p \< 0.001; ^∗∗^, p \< 0.01; ^∗^, p \< 0.05.

Deactivation of Pah1 results in decreased DAG levels, but also in accumulation of PA and, consequently, expression of genes known to be associated with phospholipid biosynthesis ([Figure 4](#fig4){ref-type="fig"}C) ([@bib27], [@bib82]). We hypothesized that rescue resulted from upregulation PA rather than a decrease in the levels of DAG. We tested this possibility by growing α-Syn-expressing yeast cells in inositol, which decreases production of PA and thus inhibits phospholipid gene expression. If this pathway was the rescue mechanism, we would expect enhanced toxicity in the presence of inositol, but we found that inositol treatment did not enhance toxicity ([Figure 4](#fig4){ref-type="fig"}D), suggesting that the reduction in DAG biosynthesis rather than accumulation of PA is relevant to the resistance of cells to α-Syn-mediated toxicity.

Chemical Inhibition of Pah1 Activity Suppresses α-Syn Toxicity in Yeast and Mammalian Cells {#sec2.6}
-------------------------------------------------------------------------------------------

To determine whether chemical inhibition of Pah1 would protect cells from α-Syn-induced toxicity, we treated α-Syn-expressing yeast cells with the well-characterized Pah1 inhibitor propranolol ([@bib45]). By monitoring biomass over 24 h, we found that 2 mM propranolol significantly suppressed toxicity in a Pah1-dependent manner ([Figure 4](#fig4){ref-type="fig"}E). This result further supports our conclusion that Pah1 activity promotes α-Syn toxicity through the conversion of PA to DAG.

To determine whether lipins (*LPIN1/2/3*), the mammalian homologs of *PAH1*, modulate α-Syn toxicity in neuronal cells, we treated mouse neuroblastoma N2A cells with fibrils pre-formed from recombinant α-Syn in the presence and absence of propranolol and assayed for cell viability. We chose this model of α-Syn toxicity because it better recapitulates PD hallmarks such as accumulation of intracellular α-Syn inclusions and neuronal toxicity than do models based on the intracellular neuronal expression of α-Syn ([@bib20], [@bib39][,]{.ul} [@bib38], [@bib78]). Administration of α-Syn fibrils to N2A cells induced toxicity in a dose-dependent manner (one-way ANOVA, p \< 0.0001). At the highest dose of administered α-Syn fibrils, cell viability was significantly increased by treatment with 10 μM propranolol ([Figure 4](#fig4){ref-type="fig"}F). In order to characterize the effects of propranolol, we conducted a shotgun phosphoproteomic analysis of α-Syn-expressing yeast cells with and without propranolol treatment. We found that the Pah1 network was affected by propranolol treatment, although various other phosphoproteins unrelated to Pah1 were also regulated ([Figure S4](#mmc1){ref-type="supplementary-material"}A; [Table S15](#mmc16){ref-type="supplementary-material"}). Finally, we silenced all three *LPIN* genes in HEK293 cells treated with α-Syn fibrils ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Treatment with α-Syn fibrils alone or silencing of *LPIN* genes alone both decreased viability of HEK293 cells; however, toxicity of α-Syn fibrils was decreased in cells in which all three *LPIN* genes had been silenced compared to control cells ([Figure 4](#fig4){ref-type="fig"}G). Overall, these results confirm our findings in yeast and indicate that inhibition of lipin activity or silencing of *LPIN* genes suppresses toxicity of α-Syn fibrils in mammalian cells.

Discussion {#sec3}
==========

α-Syn plays a crucial role in Parkinson's disease ([@bib55], [@bib65]), but the mechanisms that underlie this toxicity have remained cryptic making development of effective therapies challenging. In this study, we simultaneously measured activation states of a multitude of pathways and levels of proteins that are deregulated by expression of α-Syn across a diverse set of known genetic modulators of α-Syn toxicity. We applied multidimensional linear regression analysis to identify biological processes that correlated with the rescue from toxicity. Pah1 phosphorylation, which inhibits its activity, was predicted to protect cells from the toxic effects of α-Syn.

α-Syn expression in yeast results in lipid droplet (LD) accumulation ([@bib51], [@bib62]), and α-Syn inclusions co-localize with LDs ([@bib13], [@bib80]). Our data show that Pah1 inhibition, which antagonizes LD formation and lipid storage by halting DAG production ([@bib3]), ameliorates α-Syn-mediated toxicity and results in the reduction of α-Syn inclusion formation, suggesting tight links between α-Syn-mediated toxicity, lipid metabolism resulting in DAG production, and LD formation.

In neurons, conditions such as hypoxia, lipid-loading, and neurodegeneration induce formation of LDs ([@bib53], [@bib81]). In cultured human cells and primary neurons from mice, α-Syn binds to LDs and increases their accumulation ([@bib13]). Accumulation of α-Syn on LDs reduces hydrolysis of triglycerides contained in the droplets in mammalian cells ([@bib13]). The interactions of α-Syn with LDs may also provide a scaffold for α-Syn aggregation and for the formation of Lewy bodies ([@bib13], [@bib19]). Consistent with this hypothesis, Lewy bodies contain accumulations of lipid vesicles ([@bib63]). Alternatively, the process of α-Syn amyloid formation may be in competition with that of membrane binding. Interestingly, LDs have been implicated in several motor neuron diseases and accumulate upon neurodegeneration ([@bib53]).

Bioinformatic analyses revealed striking similarities between the membrane-targeting motif of α-Syn and that of LD-binding proteins of the perilipin (PLIN) family ([@bib15], [@bib21]). PLINs assemble on membranes containing neutral lipids and promote packaging of lipids into membrane-enclosed particles ([@bib6]). PLINs are also thought to physically protect LDs from lipase-induced lipolysis ([@bib24], [@bib76]), and PLINs associate with DAG-rich ER membranes ([@bib67]). Exogenous expression of mammalian PLINs in yeast results in a phenotype similar to that of α-Syn expression ([@bib31]). We propose that α-Syn acts as a PLIN to trigger the formation of LDs or to stabilize them once they are formed by protecting them from the action of lipases. A number of previous findings support this hypothesis: Expression of wild-type α-Syn causes accumulation of LDs, whereas expression of mutant A30P α-Syn, which has low affinity for membranes, does not cause LD accumulation in yeast ([@bib51], [@bib62]) and the A30P mutant does not bind LDs in mammalian cells ([@bib13]). Moreover, removing the N-terminal region of α-Syn responsible for membrane binding abolishes α-Syn toxicity and inclusion formation in yeast ([@bib69], [@bib79]). In addition, expression of PLINs recovers LD formation in yeast cells with defects in lipid storage caused by deletion of Pah1 ([@bib31]), similar to our observation that α-Syn expression is less toxic in *Δpah1* or *pah1*-D398E yeast mutants.

Consistent with our findings, a recent study showed that inhibition of oleic acid biosynthesis in yeast, which is a few biochemical steps upstream of Pah1, rescues cells from α-Syn-induced toxicity. Deletion of *DGA1* and *LRO1*, which encode enzymes that convert DAG to TAG, showed that DAG accumulation enhances toxicity of α-Syn possibly by increasing DAG and oleic acid levels in the ER ([@bib17]). In contrast, decreased DAG levels resulting from deletion of *TGL3*/*4* and growth in choline rescue yeast from toxicity ([@bib17]). Although a role for phospholipid biosynthesis downstream of Pah1 cannot be completely ruled out, our data and data from Fanning et al. suggest that high DAG levels are critical for α-Syn-mediated toxicity. Since yeast cells grow normally when DAG accumulates in the ER \[e.g., when *DGK1* is deleted ([@bib1], [@bib17], [@bib25])\], it is possible that DAG accumulation is only toxic in the presence of α-Syn. We speculate that α-Syn, like PLIN family members ([@bib6], [@bib15], [@bib24], [@bib31], [@bib67]), is recruited to membranes with high DAG content altering membrane properties and functions such as trafficking. It remains to be determined if inactivation of Pah1, and the resulting decrease in DAG levels, rescues yeast cells from α-Syn-mediated toxicity primarily because it prevents excessive lipid storage in LDs or because it prevents accumulation of DAG in the ER and subsequent recruitment of α-Syn. Contrasting findings have been reported regarding the toxicity of α-Syn in yeast that cannot form LDs ([@bib17], [@bib62]), and the localization of α-Syn in the absence of LDs in yeast remains to be shown.

Data from mammalian models of α-Syn toxicity and human cohorts suggest that some of the mechanisms that drive toxicity of α-Syn in yeast are conserved in higher organisms and may be relevant to PD. Our mammalian cell toxicity model is based on internalization of pre-formed α-Syn amyloid fibrils, whereas our yeast model is based on α-Syn expression. Therefore, the intracellular conformational states of α-Syn may differ in the two models. Despite this, inhibition of LPIN1/2/3 with propranolol in neuronal cells and silencing of *LPIN* genes in human cells treated with α-Syn fibrils both reduced α-Syn toxicity. Consistent with these results, silencing of all *LPIN* genes reduced α-Syn toxicity in rat cortical neurons, and DAG accumulation was detected in a PD mouse model and in neurons with an α-Syn triplication ([@bib17]). In support of our proposed mechanism and its relevance to PD, the gene coding for DGKQ, which catalyzes the conversion of DAG to PA, the reverse of the reaction catalyzed by Pah1 and LPINs, is associated with an increased risk for PD ([@bib47]).

A recent study showed that B2AR is a regulator of α-Syn expression through histone acetylation of its promoter and enhancers and that agonists of B2AR are protective in Parkinson disease models ([@bib44]). In this same study, propranolol, an FDA-approved beta-adrenergic receptor antagonist, was shown to increase α-Syn expression and to be associated with an increased risk of PD. Here we demonstrated that propranolol suppressed toxicity due to α-Syn expression in yeast and α-Syn fibril-treated neuroblastoma cells. Yeast cells used in our screen lack B2AR and α-Syn was not expressed from the endogenous promoter; therefore, in our model the protective effects of propranolol prevailed. Similarly, N2A cells, the neuronal model we used, do not express detectable levels of B2AR ([@bib28]), and toxicity was induced by exogenous pre-formed fibrils. This could explain why the protective effects of propranolol were not previously observed, but additional work will be necessary to definitively explain these findings. Given the increased risk of PD associated with propranolol use and the potential off-target effects of the drug, we do not support its testing as a PD therapy; however, more selective LPIN or CTDNEP1 (the latter is the human ortholog of yeast *NEM1*) inhibitors may hold promise for treatment of PD.

Our rapid and information-rich sentinel screening approach simultaneously measures several hundred validated biological markers, each representative of activation of the corresponding pathway or module. This screen can be tailored to include perturbation-specific markers as we did here for α-Syn. Although we focused here on Pah1, our screen predicted that modulation of other pathways leads to rescue from α-Syn-induced toxicity. One of these pathways involves Ero1, a marker for ER protein folding, a process previously implicated in α-Syn toxicity in yeast and in MPP^+^ Parkinson models ([@bib36]). Simultaneous perturbation of multiple pathways identified in our screen may also lead to stronger rescue effects. Based on our partial regression plots, alterations of the phosphorylation status of Osh1 and Num1 are promising targets to combine with deactivation of Pah1. Intriguingly, the oxysterol-binding proteins Osh2 and Osh3 were previously discovered as genetic modulators of α-Syn toxicity ([@bib84]). Num1, a protein involved in the mitochondria-ER-cortex-anchor ([@bib35]), may provide another link between α-Syn and Pah1 at the ER. We suggest testing of these candidates in future studies aimed at assessing combinatorial effects on rescue.

The network analysis of paths linking genetic modulators to Pah1 suggests mechanistic hypotheses regarding the roles of previously reported toxicity modifiers. For example, altering vesicle trafficking, and its modulators, may influence Pah1 through Nup84, a genetic interactor of the Nem1-Spo7 complex ([@bib66]). Similarly, the path from Ykt6 through the Sec1-Sso1-Sso2-Sec22 network to Pkc1 may link autophagy to Pah1 and α-Syn rescue and may explain previous reports that these processes moderate α-Syn toxicity ([@bib4], [@bib46], [@bib57], [@bib59]). Thus, the Pah1 network analysis provides context for the top candidate from our screen and is a source of testable hypotheses on interventions that could decrease α-Syn-induced toxicity. In summary, relating pathway activation data to quantitative growth assays, as we did here through linear regression analyses, allows connection of modulators to their effectors and enables formulation of testable mechanistic hypotheses. Acquiring network fingerprints across a variety of conditions may also provide ideal perturbative datasets for network reconstruction or reverse engineering and for uncovering regulatory links among pathways.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-Alpha-synuclein, mouse monoclonal \[LB 509\]AbcamCat\#ab27766; RRID:[AB_727020](nif-antibody:AB_727020){#interref155}**Bacterial Strains***E.coli*: 10-beta Competent *E. coli* (High Efficiency)New England BiolabsCat\#C3019I**Chemicals, Peptides, and Recombinant Proteins**TCEP (tris(2-carboxyethyl)phosphine hydrochloride)PierceCat\#20490; CAS\#51805-45-9IodoacetamideSigma-AldrichCat\#I1149 ; CAS\#144-48-9Ammonium bicarbonateSigma-AldrichCat\#09830; CAS\#1066-33-7UreaSigma-AldrichCat\#U5128; CAS\#57-13-6Formic acid 98-100%AppliChemCat\#A38580500Acetonitrile (HPLC)Fisher ChemicalCat\#A998; CAS\#75-05-8Trifluoroacetic acid (HPLC)Sigma-AldrichCat\#302031; CAS\#76-05-1Lysyl endopeptidaseWako Pure Chemical IndustriesCat\#125-05061Trypsin: sequencing-grade modified trypsinPromegaCat\#V5111Titansphere Phos-TiO beadsGL SciencesCat\#GL-5010-21315Reprosil-Pur 120 C18-AQ, 3 μm 15 % C endc.Dr. Maisch GmbHCat\#r13.aqReprosil-Pur 120 C18-AQ, 1.9 μm 15 % C endc.Dr. Maisch GmbHCat\#r119.aqβ-EstradiolSigma-AldrichCat\#E8875; CAS\#50-28-2G418Matthias Peter LabCAS\#108321-42-2NotI-HFNew England BioLabsCat\#R3189SXmaINew England BioLabsCat\#R0180SPropranolol hydrochlorideSigma-AldrichCat\#P0884; CAS\#318-98-9myo-InositolKarsten Weis LabCAS\#87-89-8Nile RedThermo Fisher ScientificCat\#N1142; Cas\#7385-67-3Propidium iodideSigma-AldrichCat\#P4170; CAS\#25535-16-4Recombinant α-Syn([@bib20])N/ASuperScript II reverse transcriptaseInvitrogenCat\#18064014RNaseOUT recombinant ribonuclease inhibitorInvitrogenCat\#10777019Random primersBiodynamicsCat\#B070-40**Critical Commercial Assays**BCAPierceCat\#23225CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT)PromegaCat\#G4000iRT KitBiognosys AGCat\#Ki-3002-1RNeasy Mini KitQiagenCat\#74104**Deposited Data**Shotgun DataPeptideAtlas: PASS01407<http://www.peptideatlas.org/PASS/PASS01407>PRM dataPeptideAtlas: PASS01409<http://www.peptideatlas.org/PASS/PASS01409>**Experimental Models: Cell Lines**Human embryonic kidney 293 (HEK293)ATCCCRL-1573Mouse neuroblastoma (N2A)ATCCCCL-131**Experimental Models: Organisms/Strains***S. cerevisiae*: IntTox/α-Syn: W303 MATa, can1--100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*- αSyn-YFP::*HIS3* and *GAL1*-αSyn-YFP::*TRP1*Pavan Auluck; Susan Lindquist lab; ([@bib14])N/A*S. cerevisiae*: Vector/Empty vector: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-empty::*HIS3* and *GAL1*-empty::*TRP1*Pavan Auluck; Susan Lindquist lab; ([@bib14])N/A*S. cerevisiae*: GFP: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-GFP::*HIS3* and *GAL1*-GFP::*TRP1*Pavan Auluck; Susan Lindquist labN/A*S. cerevisiae*: TDP-43-GFP: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-TDP-43::*HIS3* and *GAL1*-TDP-43::*TRP1*Pavan Auluck; Susan Lindquist labN/A*S. cerevisiae*: FUS: W303 MATα, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-FUS::*HIS3*Pavan Auluck; Susan Lindquist labN/A*S. cerevisiae*: αSyn Δ*nem1*: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*- αSyn-YFP::*HIS3* and *GAL1*-αSyn-YFP::*TRP1*, *nem1::Kan*this studyN/A*S. cerevisiae*: Vector Δ*nem1*: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-empty::*HIS3* and *GAL1*-empty::*TRP1*, *nem1::Kan*this studyN/A*S. cerevisiae*: GFP Δ*nem1*: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-GFP::*HIS3* and *GAL1*-GFP::*TRP1*, *nem1::Kan*this studyN/A*S. cerevisiae*: TDP-43-GFP Δ*nem1*: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-TDP-43::*HIS3* and *GAL1*-TDP-43::*TRP1*, *nem1::Kan*this studyN/A*S. cerevisiae*: FUS Δ*nem1*: W303 MATα, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*-FUS::*HIS3*, *nem1::Kan*this studyN/A*S. cerevisiae*: αSyn Δ*pah1*: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*- αSyn-YFP::*HIS3* and *GAL1*-αSyn-YFP::*TRP1*, *pah1::Kan*this studyN/A*S. cerevisiae*: αSyn pah*1*-7A: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*- αSyn-YFP::*HIS3* and *GAL1*-αSyn-YFP::*TRP1*, *pah1::Kan, pah1-7A::URA3*this studyN/A*S. cerevisiae*: αSyn pah*1*-7D/E: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*- αSyn-YFP::*HIS3* and *GAL1*-αSyn-YFP::*TRP1*, *pah1::Kan, pah1-7D/E::URA3*this studyN/A*S. cerevisiae*: αSyn *pah1*-D398E: W303 MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, *GAL1*- αSyn-YFP::*HIS3* and *GAL1*-αSyn-YFP::*TRP1*, *pah1::Kan, pah1-D398E::URA3*this studyN/A*S. cerevisiae*: Estradiol-inducible α-Syn: W303 can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, α-Syn::*LEU2 and* GAL4-ER-VP16*::TRP1*Saranna Fanning; Susan Lindquist labN/A*S. cerevisiae*: Estradiol-inducible α-Syn Δ*pah1*: W303 can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, α-Syn::*LEU2 and* GAL4-ER-VP16*::TRP1, pah1::Kan*this studyN/A*S. cerevisiae*: Estradiol-inducible α-Syn *pah1*-WT: W303 can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, α-Syn::*LEU2 and* GAL4-ER-VP16*::TRP1, pah1::Kan, pah1-WT::URA3*this studyN/A*S. cerevisiae*: Estradiol-inducible α-Syn pah*1*-7A: W303 can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, α-Syn::*LEU2 and* GAL4-ER-VP16*::TRP1, pah1::Kan, pah1-7A::URA3*this studyN/A*S. cerevisiae*: Estradiol-inducible α-Syn pah*1*-7D/E: W303 can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, α-Syn::*LEU2 and* GAL4-ER-VP16*::TRP1, pah1::Kan, pah1-7D/E::URA3*this studyN/A*S. cerevisiae*: Estradiol-inducible α-Syn *pah1*-D398E: W303 can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, α-Syn::*LEU2 and* GAL4-ER-VP16*::TRP1, pah1::Kan, pah1-D398E::URA3*this studyN/A**Oligonucleotides**See [Table S16](#mmc17){ref-type="supplementary-material"}this studyN/A**Recombinant DNA**α-Syn modulator plasmids: each gene in [Table S5](#mmc6){ref-type="supplementary-material"} in pBY011; CEN, URA3, Amp^R^([@bib14])N/ApFA6a-KanMX6([@bib37])N/ApGH315, *pah1* Inserted into pRS415([@bib10])N/ApGH315(7A), *pah1* (S110A/S114A/S168A/S602A/T723A/S744A/S748A) inserted into pRS415([@bib10])N/ApGH315(7D/E), *pah1* (S110D/S114D/S168D/S602D/T723E/S744D/S748D) inserted into pRS415([@bib30])N/ApGH312(D398E), HA-tagged *pah1* (D398E)([@bib26])N/ApRS306, yeast integrative vector with URA3 markerMatthias Peter LabATCC 77141pMS1, *pah1*-WT inserted into pRS306this studyN/ApMS2, pah*1*-7A inserted into pRS306this studyN/ApMS3, *pah1*-D398E inserted into pRS306this studyN/ApMS4, pah*1*-7D/E inserted into pRS306this studyN/A**Software and Algorithms**Skyline-daily v 2.0.9.4899Michael MacCoss lab<https://skyline.ms/project/home/software/Skyline/begin.view>R v. 3.1.1 & 3.5.1The R Project for Statistical Computing<https://www.r-project.org/>MSstats v. 0.99([@bib11])<http://bioconductor.org/packages/release/bioc/html/MSstats.html>Proteome discoverer v. 1.4 & 2.0Thermo Fisher Scientific<https://www.thermofisher.com/ca/en/home.html>Xcalibur v. 3.1Thermo Fisher Scientific<https://www.thermofisher.com/ca/en/home.html>Progenesis QINonlinear dynamics<http://www.nonlinear.com/progenesis/qi-for-proteomics/>SafeQuant v. 2.01([@bib23])<https://cran.r-project.org/web/packages/SafeQuant/index.html>FunSpec([@bib58])<http://funspec.med.utoronto.ca/>Saccharomyces Genome Database (SGD)([@bib9])<https://www.yeastgenome.org/>ImageJ v 1.47dWayne Rasband, National Institutes of Health, USA<https://imagej.nih.gov/ij/>CellProfiler v. 3.1.8CellProfiler cell image analysis software<https://cellprofiler.org/>STRING v. 10.5 & 11.0([@bib75])<https://string-db.org/>c060 v. 0.2-4([@bib64])<https://cran.r-project.org/web/packages/c060/index.html>igraph v. 1.2.4([@bib16])<https://cran.r-project.org/web/packages/igraph/index.html>network v. 1.15([@bib7])<https://cran.r-project.org/web/packages/network/index.html>ggnetwork v. 0.5.1([@bib5])<https://cran.r-project.org/web/packages/ggnetwork/index.html>GraphPad Prism v 7.0cGraphPad<https://www.graphpad.com/>**Other**FastPrep-24 5GMP biomedicals<https://ch.mpbio.com/>BioLectorm2p labs<https://www.m2p-labs.com/bioreactors/products/biolector/>FACSCalibur flow cytometerBD Biosciences<https://www.bd.com/>DM6000B microscopeLeica microsystems<https://www.leica-microsystems.com/>Eclipse Ti microscopeNikon<https://www.microscope.healthcare.nikon.com>Q-Exactive Plus mass spectrometerThermo Fisher Scientific<https://www.thermofisher.com/ca/en/home.html>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Paola Picotti (<picotti@imsb.biol.ethz.ch>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Saccharomyces cerevisiae {#sec4.3.1}

Yeast W303 cells were grown at 30°C in synthetic defined (SD) medium picked from a single colony and sampled at 6 h post-induction of α-Syn from log-phase growth, except where specified in [Method Details](#sec4.4){ref-type="sec"}.

### Mammalian Cell Lines {#sec4.3.2}

Human embryonic kidney 293 (HEK293) cells (sex: female) were grown in Dulbecco's Modified Eagle Media (DMEM) with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (Pen-Strep) at 37°C and 5% CO~2~. Mouse neuroblastoma (N2A) cells (sex: male) were maintained in DMEM with 10% FBS and 1% Pen-Strep, and grown in DMEM with 2% FBS and 1% Pen-Strep when treated with α-Syn pre-formed fibrils. Cell lines were passaged up to 5 times and routinely tested negative for mycoplasma contamination.

Method Details {#sec4.4}
--------------

### Yeast Strain Phenotyping {#sec4.4.1}

Cells were grown overnight at 30 °C in synthetic defined (SD) liquid medium containing 2% glucose with appropriate dropout and then diluted and grown overnight in 2% raffinose dropout medium. To induce α-Syn expression, cells were diluted to 0.3 OD~600~ in 2% galactose SD medium. Live cells were imaged on a Leica DM6000B microscope with a 60X objective in the GFP channel. Images were processed in ImageJ.

For growth assessment, 100 μl of a 0.15 OD~600~ culture in 2% galactose SD medium was transferred to a 96-well plate. Biomass (measured by monitoring 620 nm) was recorded for 24 h by a BioLector microbioreactor. The system was set to a temperature of 30 °C, humidity of 85%, 20.95% O~2~, and 800 rpm. The baseline was established on a well-by-well basis according to the average signal of the six time points with the lowest standard deviation across the dataset. Errors are the standard deviations of three biological replicates.

For viability measurements, 100 μl of sample was diluted to 1 ml with PBS and 1 μl of 2 mg/ml propidium iodide was added. Samples were incubated on ice for 10 min in the dark. Cells were pelleted, and the supernatant was discarded. To the sample was added 1 mL of PBS, and 10,000 cells were analyzed by flow cytometry (emission at 617 nm, excitation at 535 nm).

### Shotgun Proteomic Analysis {#sec4.4.2}

Shotgun proteomic measurements and label-free quantification were carried out on the yeast strain with two copies of α-Syn (IntTox strain) and an empty vector-containing control at 6 h post induction. This time point was selected because α-Syn-YFP inclusions were visible, growth curves of vector- and α-Syn-expressing cells had begun to separate, and death rates were negligible. Cell pellets were mechanically disrupted by bead beating in a FastPrep-24 5G device, protein lysates were digested with trypsin and Lys-C, and peptides were purified and phosphopeptides were isolated using Titansphere Phos-TiO beads as previously described ([@bib70]). Peptides were chromatographically eluted from a 50-cm heated column (60 °C) packed with 1.9-μm C18 beads using a 2-h gradient of 5% to 35% acetonitrile. Peptides were analyzed on a Q-Exactive Plus mass spectrometer operated in DDA mode. Proteins and phosphopeptides were identified by searching the SGD Protein Database with a peptide false discovery rate of \< 0.01 using Proteome Discoverer software. MS1 peak identification by Progenesis and quantification and plotting by Safequant ([@bib23]) were used to find significantly regulated features (fold change ≥ 2, q ≤ 0.01). Functional enrichment analysis was carried out using FunSpec ([@bib58]). GO ([@bib2]) and MIPS ([@bib43]) categories were searched. For enriched categories, a significance cutoff of p-value ≤ 0.05 with Bonferroni correction was used.

### Quantification of Modulator Rescue {#sec4.4.3}

For genetic modulation of toxicity, α-Syn-expressing and empty vector-expressing strains were transformed with an extrachromosomal plasmid for galactose-inducible expression of modulators ([@bib14]). α-Syn yeast strains expressing the different modulators were cultured in four batches. For the first three batches (13 modulators), cells were grown as described above in three biological replicates. The additional 20 modulators were tested in singlicate as a fourth batch. For induction of α-Syn and modulator expression, cells were diluted to 0.15 OD~600~ in 2% galactose SD medium. Growth was assessed in technical duplicates or triplicates as described above in a microbioreactor. Biomass values were used to quantify rescue. Baselines were established on a well-by-well basis based on averaged signals of the first six time points, then all biomass values over 24 h were summed. The specific rescue by each modulator was calculated by dividing the ratio of the biomass of strain expressing α-Syn plus modulator to strain expressing α-Syn alone by the ratio of the biomass of strain expressing vector plus modulator to vector alone. The mean value of replicates was used for modulators tested in triplicate.

### Addition of α-Syn-Specific Markers to the Sentinel Assay {#sec4.4.4}

In addition to monitoring generic yeast cellular process (phospho)protein markers ([@bib70]), α-Syn-specific markers were selected from the significantly regulated (phospho)proteins identified in the shotgun proteomic analysis (fold change ≥ 2, q ≤ 0.01). Proteotypicity was verified, and these targets were measured by PRM targeted mass spectrometry in order to confirm the label-free quantification. Markers were prioritized if the amplitude of their response in PRM and shotgun data was high indicating a greater likelihood for detection in a multiplexed PRM assay and potentially large fold change induced by α-Syn. Phosphopeptide targets were also preferred if their respective protein occurred multiple times in the candidate list, potentially suggesting multiple PTM changes caused by α-Syn. (Phospho)proteins were also prioritized based on their functional characterization and prior knowledge of how this may relate to known α-Syn biology or may lead to novel findings in the case of uncharacterized candidates. Finally, (phospho)proteins with a human homolog were favored to facilitate future testing. Using these criteria, 29 proteins and 65 phosphopeptides were added as α-Syn-specific sentinels. Assays were also generated for S87 phosphorylated α-Syn (added to phosphorylation assay), K12-, K21-, and K96-ubiquitinated α-Syn, the propeptide (YMR297Wpro), and the mature (YMR297Wmat) forms of Cpy1 (all added to protein assay) based on literature evidence of involvement in toxicity. The final proteomic assay attempted to monitor a total of 376 pathway sentinels (188 proteins and 188 phosphopeptides), 26% of which were α-Syn-specific.

### Pathway Monitoring across α-Syn Modulators {#sec4.4.5}

Quantification of sentinels was done using targeted proteomics as previously described ([@bib70]) except for two differences: the addition of α-Syn-specific sentinels and adaptation of the assay from selected reaction monitoring to PRM mass spectrometry. The assay was implemented on a Q-Exactive Plus mass spectrometer operated in PRM mode. Peptides were eluted from a 20-cm column packed with 3-μm C18 beads using a 5% to 35% acetonitrile gradient over 40 min. iRT peptides were used for scheduling 3-min windows for detecting each target. Raw PRM traces were manually evaluated in Skyline and 3-10 transitions per target and per analysis batch were exported for normalization and quantification by MSStats ([@bib11]). Phosphopeptides and proteins not detected in at least one sample were removed. If a peptide was determined to be detected in all samples but one or more low intensity transitions in some samples had a peak area less than an average noise value (6 transition peak areas where no peptides are detected) then the average noise value, across all batches, was input for the quantification. For protein quantification, noise value was set to a peak area of 2080 and for phosphopeptide quantification, the noise value was set to 3466. In total, 0.0018 of the quantified values were noise values. In total 269/376 sentinels were quantified across 33 genetic modulators in four separate batches. One empty vector, without α-Syn, and one unmodulated α-Syn sample were analyzed in each batch.

### Data Processing and Modeling of Rescue {#sec4.4.6}

Using the quantified results from MSStats, a phosphopeptide matrix and a protein matrix were created that contained log~2~ fold change values relative to the vector sample for 103 phosphosites and 166 proteins across the 37 samples. We corrected for batch effects by subtracting the median value over the batch from the corresponding samples. We chose to use the median as opposed to the mean for robustness against outliers. Protein and phosphopeptide features were hierarchically clustered in rows according to batch-corrected fold change values relative to the vector samples and using Euclidean distance and the complete linkage method.

We modeled the rescue effect *Y* as a function of the activities of all sentinels *S*~*j*~ (i.e., the pathway marker abundance values) across all genetic modulators *i*:$$Y_{i} = \alpha + \sum\limits_{j}\alpha_{j}S_{ij} + \mathit{\epsilon}_{i}\ $$

Here, $Y_{i}$ is the growth effect of modulator *i* relative to the wild-type control, and $S_{ij}$ is the activity (abundance) of sentinel *j* for the *i*^th^ modulator. The fitting parameter *α*~*j*~ is the partial effect of sentinel *j* on the rescue, and *α* is the intercept. Since all sentinels are modeled together the effect of the *j*^th^ sentinel is estimated as if all other sentinels were held constant. The error term in the model is denoted by *ϵ*~*i*~. In order to retrieve the most relevant sentinels, we aimed to obtain a sparse model using lasso with stability selection ([@bib42]). Stability selection is a general approach that combines (regularized) regression models with resampling and aims to find stable sentinels showing strong association with the rescue. Specifically, we used the function 'stabpath' from the R package 'c060' ([@bib64]) with default parameters. The stability selection algorithm was applied twice: once for the phosphopeptides and once for the proteins. We used the average log~2~ rescue as a response variable. The input variables were the batch-corrected log~2~ fold changes of all 103 phosphopeptides and the batch-corrected log~2~ fold changes of all 166 proteins. The protein YMR297W (Cpy1) is a degradation-based sentinel; an increase in propeptide abundance relative to total protein abundance reports the known α-Syn induced block in ER to Golgi vesicle trafficking. The two features YMR297Wpro and YMR297Wmat were therefore counted as one protein sentinel and removed from the protein matrix so that the difference between their values could be considered instead (ratio in the raw space). It was necessary to use regularization since the number of observations/samples (n = 37) is much smaller than the number of variables (p = 103 and 166, respectively). Stable features were classified as sentinels with a maximal selection probability ≥ 0.6. In order to determine the sign of the effect (i.e., coefficient) of the stable features, we fit a linear model, one for the phosphopeptides and one for the proteins, with the same response variable but with the fold changes of the stable features as the sole input variables. As opposed to simple linear regression/correlation analysis, in multiple linear regression the coefficient of each feature measures the effect of that feature on the output given that the values for all other features in the model are held constant. Equivalently, it measures the unique effect of that feature on the output by removing the linear effects of all other features. When two sentinels are correlated to each other (positively or negatively) the coefficients in the combined model may deviate substantially from simple pairwise correlations between sentinels and responses.

### Enrichment Analysis of Sentinels Oppositely Regulated between Enhancers and Suppressors {#sec4.4.7}

A cluster of 107 sentinels was observed to be oppositely regulated when comparing genetic enhancers and suppressors of toxicity. These sentinels mapped to 100 unique yeast proteins. Funspec was used to test for functional classes enriched in this set of proteins. Using Bonferroni correction and a p-value cutoff of 0.05, GO and MIPS categories were identified.

### Network Analysis of α-Syn Genetic Modulators and Pah1 Regulators {#sec4.4.8}

The STRING network for *Saccharomyces cerevisiae* was filtered for high-confidence edges (interaction score above 0.9), and subsequently the largest connected component was retained. This consisted of 4,084 nodes and 54,540 edges. The *Saccharomyces* genome database was used to link systematic names (STRING identifiers) and standard names ([@bib9]). Of the 33 genetic modulators, 25 were present in the largest component. Pah1 was also present in this component. For each of the 25 modulators present in the largest connected component we computed all shortest paths to each of the following upstream regulators of Pah1: Nem1-Spo7 complex components (Nem1, Spo7), Cdc28, PKA complex components (Bcy1, Tpk1/2/3), casein kinase II complex components (Cka1/2, Ckb1/2), Pho80-85 complex (Pho80, Pho85), and Pkc1. This procedure identified the shortest path (or paths) from each modulator to all 14 regulators of Pah1 phosphorylation. We kept the shortest (of the shortest to all regulators) in order to identify the closest of the 14 Pah1 regulator(s). Ties can arise at two stages: if more than one regulator is equally close to a given genetic modulator and if there are multiple shortest paths leading to the same closest regulator. In the case of ties, we kept all shortest paths for the subsequent analysis. The nodes included in the shortest (of the shortest) paths, together with Nem1, Pho80, and Pho85 (i.e., protein Pah1 regulators that are not the closest target of any of the 25 modulators), were used to finally generate the subnetwork. The closest regulator was annotated for each modulator. Eight modulators not found in the largest component were kept as isolated nodes. Since the STRING network is undirected, we excluded Pah1 from the largest connected component when computing the shortest paths because we assumed that Pah1 is the downstream endpoint of the regulators (i.e., to avoid artifacts, the discovered shortest path was not permitted to go from a modulator through Pah1 to one of the regulators).

In order to annotate the correspondence between Pah1 phosphorylation fold change (FC) induced by a given modulator and the network path distance of the same modulator to the closest Pah1 regulator, the absolute FC value was plotted against the length of the shortest distance path. Infinite (Inf) indicates that the modulator was not connected to any Pah1 regulator in the network. To test if modulators closer to Pah1 regulators had a greater average absolute FC, a one-tailed (two-sample) t-test was applied to the group of modulators at shortest distance equal to 1 or 2 compared to those at 3, 4 or Inf.

In order to identify central nodes, we computed for each node of the subgraph its betweenness (i.e., the number of shortest paths going through that node). More specifically, the betweenness centrality of a node $v$ is given by the expression:$$g\left( v \right) = \sum\limits_{s \neq v \neq t}\frac{\sigma_{st}\left( v \right)}{\sigma_{st}}$$where $\sigma_{st}$ is the total number of shortest paths from node $s$ to node $t$ and $\sigma_{st}\left( v \right)$ is the number of those paths that pass through $v$. This score was chosen as a measure of centrality because we previously computed the shortest paths in order to generate the subnetwork.

### Strain Construction and Growth Assessment {#sec4.4.9}

Deletions of *NEM1* and *PAH1* were done using standard procedures by targeting the KanMX cassette to each target gene ([@bib37]). Colonies selected by growth in G418 were confirmed to have the correct gene deletion by PCR and sequencing. *pah1*-WT, *pah1--7A*, *pah1--7D/E*, and *pah1*-D398E genes were amplified from plasmids that were a generous gift from George Carman and Gil-Soo Han (Rutgers University) ([@bib10]) and were integrated at the *URA* locus via the vector pRS306. Yeast transformations were done using standard procedures. Serial dilutions of 0.3 OD raffinose cultures of yeast strains were spotted onto glucose and galactose plates and imaged 3 days after spotting in biological triplicate.

### Live-Cell Microscopy {#sec4.4.10}

Fluorescence microscopy images were taken 6 h post induction in a 96-well plate mounted on the stage of a Nikon Eclipse Ti microscope equipped with a 100x oil objective. α-Syn was imaged in the YFP channel. Z stacks were acquired at 0.25-μm intervals, and the resulting images were merged to maximum intensity projections in ImageJ. Cells with and without visible inclusions were counted manually in ImageJ. At least 95 cells were counted in each of three fields of view, and the results were averaged and tested for significance by one-way ANOVA adjusted for multiple comparisons. Imaging was conducted in at least biological triplicate, except for α-Syn-expressing Δ*pah1*, *pah1*-D398E, and *pah1*-7D/E, which were each evaluated once. For these latter strains, three or four different fields of view were used for statistical testing. The α-Syn-expressing Δ*nem1* and α-Syn strains were stained with Nile red using a final concentration of 0.5 μg/mL. After 5 min incubation at 30 °C, cells were washed with PBS before live cell imaging. Nile red staining was imaged in the RFP channel.

For assessment of co-localization and quantification of Nile red intensity, three regions of interest (ROI) from three fields of view per biological replicate were used as input for a co-localization pipeline in CellProfiler. Nile red and YFP channels were measured across the entire ROI with a threshold of 15% of maximum intensity and reported normalized covariance (Pearson r). To quantify lipid abundance, objects were identified in images with a diameter range of 20-100 pixels. An average of 252 Nile red positive objects and 409 YFP-positive objects were found per biological replicate. Three biological replicates were assessed for α-Syn and α-Syn Δ*nem1* samples, and two biological replicates were tested for α-Syn *pah1*-7A. A module was added to the pipeline in order to measure the Nile red intensity only within areas enclosed by Nile red-positive objects. The integrated intensity of the sum of pixel intensities within an object (arbitrary units) was used for quantification. Pearson r and integrated intensity values were averaged across all ROIs and images within each biological replicate of a given sample.

### Quantification of α-Syn Abundance {#sec4.4.11}

α-Syn abundance in α-Syn-expressing Δ*nem1*, *pah1-*WT, and *pah1-7A* yeast was assessed by western blot (anti-α-Syn, ab27766, Abcam), and equal loading of total protein was confirmed by Ponceau staining.

### Quantification of Pah1 Phosphorylation {#sec4.4.12}

Phosphopeptides were enriched from whole-cell lysates as described above. PRM was used to quantify 18 transitions from two phosphopeptides mapping to three known Nem1-target phosphosites and 11 transitions from two phosphopeptides containing two phosphosites not targeted by Nem1. Abundances were determined using MSStats and normalized by total ion chromatogram and Pah1 protein abundance measured from protein lysates. Abundance levels were quantified by summed transition area relative to mean sum transition areas in vector sample for each peptide across biological triplicates. Mean abundances for Nem1 target and non-target phosphopeptides were compared between α-Syn and α-Syn Δ*nem1* by two-way ANOVA adjusted for multiple comparisons, *n*=6, alpha=0.05 in order to assess if Pah1 phosphorylation was significantly different at Nem1-target sites and at non-target sites.

### Pah1 Perturbation and Rescue Assessment {#sec4.4.13}

Suppression or enhancement of toxicity in *PAH1* mutants and due to chemical treatments was assessed as described above for modulator rescues. Normalized biomasses were calculated by dividing raw sum biomass values for each sample by the average signal intensity for all samples per replicate in order to eliminate technical variation between replicates measured at different times. Yeast with the estradiol transcriptional regulator integrated at the *TRP* locus and α-Syn under the control of an estradiol-regulated promoter at the *LEU* locus were cultured in galactose media and induced to express α-Syn by growth in media containing 1 nM estradiol dissolved in DMSO. Vector control was treated with DMSO only. Based on a previous report ([@bib27]), 75 μM inositol was added to media in order to inhibit expression of genes involved in phospholipid biosynthesis. Propranolol was dissolved in water and spiked into cultures at 2 mM; control samples were treated with water only. The concentration of 2 mM propranolol was previously used to inhibit Pah1 in yeast ([@bib61]). Shotgun proteomics for protein and phosphopeptide abundance changes in propranolol treated α-Syn yeast versus untreated α-Syn yeast was conducted as described above except Proteome Discoverer v2.0 was used for label-free quantification. Samples were harvested for analysis 24 h post-estradiol induction of α-Syn. A fold-change cutoff of 2 and a q value ≤ 0.05 were used to identify regulated proteins and phosphopeptides. The corresponding proteins of regulated phosphopeptides were input into STRING v11.0 in order to find clusters of interacting proteins. A confidence threshold of 0.9 interaction score was applied, disconnected nodes were omitted and K-means clustering was set to 10.

### Analysis of Interactions between α-Syn Expression and *PAH1* Mutants {#sec4.4.14}

We tested for interactions between the α-Syn perturbation and each *PAH1* mutation. We defined the expected effect on growth as the product of the biomass of the individual perturbations (biomass(α-Syn) ^∗^ biomass(*pah1*-mutant)). This method has been used to define a neutrality function that predicts the phenotype of two non-interacting mutations ([@bib41]). We then compared the actual observed phenotype of the double-perturbation (biomass(α-Syn + *pah1*-mutant) to determine if it was significantly different than the expected phenotype.

### Suppression of Toxicity by Propranolol in Mammalian Neuroblast Cells {#sec4.4.15}

N2A cells were incubated for 24 h with PBS or exogenous α-Syn fibrils (0.25 and 1 μM) produced from recombinant α-Syn as previously described ([@bib20], [@bib38]). Cells were treated with vehicle or 10 μM propranolol for 36 h, and cell viability was assessed by MTT assay (Promega). Compared to the yeast experiment, a lower dose of propranolol was used on N2A cells since yeast have a cell wall and N2A cells do not.

### Suppression of Toxicity by Knockdown of Lipin Genes in Human Cells {#sec4.4.16}

HEK293 cells were transfected with a control siRNA (cat\# D-001810-01-05, Dharmacon) or a pool of siRNAs targeting the *PAH1* orthologs, *lipin1*, *lipin2*, and *lipin3* (*LPIN1*a: cat\# J-017427-09-0002, *LPIN1*b: cat\# J-017427-11-0002, *LPIN2*a: cat\# J-013458-09-0002, *LPIN2*b: cat\# J-013458-11-0002, *LPIN3*a: cat\# J-032702-07-0002, *LPIN3*b: cat\# J-032702-08-0002, all from Dharmacon). After transfection, the cells were treated with exogenously produced α-Syn fibrils (1 μM). Viability was assessed by MTT assay.

The efficiency of siRNA-mediated knockdown of *LPIN* genes was assessed by RT-PCR. HEK293 cells were transfected with siRNAs, and the mRNAs of each *LPIN* gene were amplified by non-saturating PCR. *HSC70*, an unrelated mRNA, was used as a loading control. For RT-PCR, total RNA was isolated from the cells using RNeasy Mini Kit following manufacturer's instructions. For reverse transcription, 1 μg of RNA was incubated for 1 h at 37° C with SuperScript II reverse transcriptase in the presence of RNaseOUT RNase inhibitor and random primers, followed by an inactivation step at 95 °C for 5 min. The obtained complementary DNA (cDNA) was used as template in a 28-cycle PCR performed with the following specific primers: human *LPIN1* fwd: TGCTGGAGAGCAGCAGAACTC; human *LPIN1* rev: TAGGGTATGAGGCTGACTGAG; human *LPIN2* fwd: CCTCTCCTCAGACCAGATCG; human *LPIN2* rev: GGAGAATCTGTCCCAAAGCA; human *LPIN3* fwd: CACTCCACCCTCCACTCCTA; human *LPIN3* rev: ACAGGTAGATGGTGGCCTTG; human *HSC70* fwd: GGAGGTGGCACTTTTGATGT and human *HSC70*: GTACGGAGGCGTCTTACAGC. Amplified products were electrophoresed in a 1.5% agarose gel and stained with SYBR Green PCR.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical tests were performed using SafeQuant (v. 2.01), MSstats (v. 0.99), Proteome Discoverer (v. 2.0) and GraphPad Prism (v. 7.0c). Methods of quantification and statistical analysis, including which test was used, the value and meaning of n, definition of center and dispersion and precision measures are included in the figure legends and Method Details section of the corresponding experiment. Unless otherwise specified, n denotes the number of independent biological samples tested in the experiment. Data in bar and box plots are represented as mean ± Standard Deviation (SD). Significance levels are defined in the figure and table legends. No explicit methods were used to test whether the data met certain assumptions or to determine strategies for randomization, sample size estimation and inclusion or exclusion of any data. For the regression and network analyses, the statistical language R (v. 3.5.1) has been used. In particular, for the regression analysis (stability selection) the R package 'c060' (v. 0.2-4) was used, while for the network analysis and the network visualization we have used the R packages 'igraph' (v. 1.2.4) ([@bib16]), 'network' (v. 1.15) ([@bib7]) and 'ggnetwork' (v. 0.5.1) ([@bib5]). All the details of the methods, including thresholds, sample size and number of variables/parameters, can be found in the Method Details and the figure legends.

Data and Code Availability {#sec4.6}
--------------------------

The accession number for the proteomics shotgun data reported in this paper is PeptideAtlas: PASS01407 (<http://www.peptideatlas.org/PASS/PASS01407>). The accession number for the proteomics PRM data reported in this paper is PeptideAtlas: PASS01409 (<http://www.peptideatlas.org/PASS/PASS01409>).
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Document S1. Figures S1--S4Table S1. Shotgun Proteomic Analysis of α-Syn Yeast, Related to Figure 1B, S1D--S1G and STAR Methodsα-Syn and vector samples in biological triplicate were harvested at 6 hr post-induction of α-Syn. Peptides from protein lysates and phosphopeptides enriched from protein lysates were analyzed by LC-MS/MS. Label-free quantification was carried out by Progenesis (Nonlinear Dynamics) and Safequant ([@bib23]). Significant differences (medianRatio ≥ 2 or ≤ 0.5 and q value ≤ 0.01) are highlighted in green. Previously identified overexpression suppressors ([@bib33], [@bib84]) found to be upregulated are highlighted in red.Table S2. Functional Enrichment Analysis Results for Significantly Regulated Proteins and Phosphoproteins, Related to Figures S1D--S1G and STAR MethodsAll GO and MIPS categories searchable by FunSpec and found to be enriched in significantly regulated (phospho)proteins are reported. 333 unique systematic names for proteins were used as input. Phosphosites were ignored and the corresponding protein was used. Bonferroni correction was used and a p-value cutoff of 0.05 was selected. k corresponds to the number of ORFs in the input cluster and f to the number of total ORFs in the given category.Table S3. Precursor List for Targeted Measurement of Pathway Sentinels, Related to Figure 1B and STAR MethodsBoth generic and α-Syn-specific sentinels are included. Precursor lists were used for parallel reaction monitoring mass spectrometry. Peptides for protein targets and phosphopetides for phosphorylation site targets were measured separately. iRT was used to schedule measurements for each batch of genetic modulators.Table S4. Number of α-Syn-Specific Sentinels Added to Generic Yeast Pathway Sentinels, Related to Figure 1B and STAR MethodsGeneric assays are from ([@bib70]) and α-Syn specific assays were selected from candidates identified in [Figures S1](#mmc1){ref-type="supplementary-material"}D--S1G; [Table S1](#mmc2){ref-type="supplementary-material"}.Table S5. Thirty-three Previously Identified Genetic Modulators of α-Syn Toxicity Analyzed in This Study, Related to Figures 1A and 1B, Figures S1H and S1I and STAR MethodsThe source which identified each genetic modulator is indicated. Sentinel analysis was conducted in four batches where the first three were done in biological triplicate and the fourth as singlicate. The cellular process of each genetic modulator was annotated.Table S6. Searchable Version of the Heatmap Displaying Sentinel Quantification Across Genetic Modulators, Related to Figure 1BColumns are modulator genes and rows correspond to each quantified sentinel (phospho)protein. Values are batch-corrected fold changes relative to abundance in the vector strain. These values were used for regression analysis by stability selection.Table S7. Biomass Values Used to Calculate Rescue for Use in the Regression Model, Related to Figures 1B and 1C, Figure S1H, and STAR MethodsSamples are separated by growth analysis batch, strain (vector or α-Syn), the modulator expressed (mod) and the biological replicate (biorep). Biomass values are the sum of all datapoints measuring light scatter (620 nm) over 24 h.Table S8. Open Reading Frames of Sentinels from Cluster in Figure 1B that Showed Opposite Behavior in Enhancers and Suppressors of Toxicity, Related to Figure 1B (Gray Bar) and STAR MethodsThis list of open reading frames (ORFs) was used as input for FunSpec enrichment analysis. For phosphoprotein sentinels, the phosphosite was ignored for enrichment analysis and only the corresponding ORF was used as input to FunSpec.Table S9. Functional Enrichment Analysis Results for Cluster of Oppositely Regulated Sentinels in Enhancers and Suppressors of Toxicity, Related to Figure 1B and STAR MethodsAll GO and MIPS categories searchable by FunSpec and found to be enriched in the ORF input cluster (n = 100) are reported. Bonferroni correction was used and a p-value cutoff of 0.05 was selected. k corresponds to the number of open reading frames (ORFs) in the input cluster and f to the number of total ORFs in the given category.Table S10. Ranked List of Phosphopeptide Sentinels Output from Stability Selection Analysis, Related to Figure 1C and STAR MethodsRanking is according to maximal selection probability. A cutoff of 0.60 was chosen to classify stable features contributing to rescue.Table S11. Ranked List of Protein Sentinels Output from Stability Selection Analysis, Related to Figure 1C and STAR MethodsRanking is according to maximal selection probability. A cutoff of 0.60 was chosen to classify stable features contributing to rescue.Table S12. Sentinel (Phospho)proteins Representing Pathways Predicted to Rescue from α-Syn Toxicity, Related to Figures 1C and 1D, Figure S2D, and STAR MethodsStability selection analysis was performed on sentinel (phospho)protein abundance and rescue quantification data to find predictive sentinels. Predictive sentinels correspond to those with a selection frequency in the model greater than or equal to 60% (maximal selection probability ≥ 0.60), the selected threshold for contribution to rescue. A coefficient/partial effect value was found for each sentinel that passed the selection frequency cutoff through multiple linear regression and denotes the direction of regulation which correlates with rescue. Pathway describes the general pathway each sentinel is involved in. For generic sentinel (phospho)proteins, Sentinel lists which process the marker reports on ([@bib70]). α-Syn-specific sentinels do not have a Sentinel term since they were added, not as biologically validated generic markers, but instead to specifically assay α-Syn modulators.Table S13. Shortest Paths Linking Genetic Modulators to Pah1 Regulators and Node Centrality Measure for the Subgraph of Shortest Paths, Related to Figures 2A and 2B and STAR MethodsThe shortest path(s) are shown for each genetic modulator linked to a known Pah1 regulator in the STRING network for Saccharomyces cerevisiae. The STRING network was filtered for high-confidence score edges (interaction score \> 0.9). To assess centrality for each node in the subgraph of shortest paths, a betweenness score was computed.Table S14. Transitions Used to Quantify Pah1 Phosphorylation, Related to Figure 3B and STAR MethodsAverage peak areas of transitions for peptides containing Nem1 target and non-target phosphorylation sites were monitored. The data was normalized by total ion chromatogram and the average peak areas of transitions from unmodified Pah1 peptides. \[+16\] indicates oxidation of methionine and \[+80\] indicates phosphorylation of serine.Table S15. Shotgun Proteomic Analysis of α-Syn Yeast Treated with Propranolol, Related to Figure 4E, Figure S4A, and STAR MethodsBiological triplicates were harvested at 24 h post-induction of α-Syn by estradiol and addition of propranolol. Peptides from protein lysates and phosphopeptides separately enriched from protein lysates were analyzed by LC-MS/MS. Label-free quantitation was carried out by Proteome Discoverer and significant differences are shown here for +propranolol/-propranolol control (Abundance Ratio ≥ 2 and Abundance Ratio Adjusted p value ≤ 0.05).Table S16. Oligonucleotides Used in This Study, Related to Figures 3 and 4 and STAR MethodsThese oligonucleotides were used to generate deletion strains in yeast and to silence the *LPIN* genes in human cells.Document S2. Article plus Supplemental Information
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